April 2014, Part 1
Introducing Immunotherapy in Oncology: A 4-Part Supplement Series to Personalized Medicine in Oncology
Personalized Medicine in Oncology (PMO) is proud to present a 4-part supplement series to our reading community focused on the timely issue of immunotherapy and its role in personalizing cancer care. Harnessing the power of the immune system to combat cancer is not a new idea; however, the new generation of immunotherapeutic agents has captured the imagination of those in the oncology community and sparked a renewed interest in the potential capabilities of an empowered immune system.
Immunotherapy in Oncology will explore the new generation of immunotherapies as monotherapy, as well as in combination with molecularly targeted therapies: the combination of these agents has been shown to complement each other’s mechanisms and may possess therapeutic synergy. Immunotherapy has a significant role in today’s treatment of patients with cancer, and it is imperative that physicians and patients have knowledge of the latest information in immunotherapy’s offerings.
We hope this offering empowers you to provide the very best in patient care.
Sanjiv S. Agarwala, MD
St. Luke’s Medical Center PMO Editor in Chief
The idea of harnessing a patient’s own defenses and actively augmenting a deficient immune response to help fight disease has been implemented since the 18th century. Adoption of immunotherapy into clinical practice has been difficult until recently, when many late-stage clinical trials demonstrating an overall survival (OS) advantage in melanoma [ Read More ]
With several agents now approved and broadly available for the treatment of patients with advanced renal cell carcinoma (RCC), a great deal of attention has been focused on determining the most appropriate sequence of therapies. The concept of sequential therapy has developed for several reasons, including: (1) the availability of [ Read More ]